SCHEMBL21725488

SCHEMBL21725488

CCCC(C)c1ccc(F)cc1C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.39
DPP4 P27487 1/20 0.38
SLC6A2 P23975 6/20 0.36
SLC6A4 P31645 6/20 0.36
SLC6A3 Q01959 1/20 0.36
PDE2A O00408 3/20 0.36
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
PPARG P37231 2/20 0.32
EPHX2 P34913 1/20 0.32
P2RX7 Q99572 2/20 0.32
RORC P51449 1/20 0.31
SCN1A P35498 1/20 0.31
SCN5A Q14524 1/20 0.31
SCN8A Q9UQD0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23101907 0.87 SLC6A2 (0.39) IDO1DPP4SLC6A2SLC6A4SLC6A3
SCHEMBL12058638 0.86 IDO1 (0.41) IDO1DPP4SLC6A2SLC6A4SLC6A3
SCHEMBL20085641 0.86 IDO1 (0.41) IDO1DPP4SLC6A2SLC6A4SLC6A3
SCHEMBL1913771 0.82 TYR (0.34) PDE2AALDH1A1RORC
SCHEMBL21725452 0.82 HTT (0.36) PDE2AALDH1A1P2RX7
SCHEMBL19098547 0.79 MC4R (0.39) IDO1SLC6A2SLC6A4SLC6A3PDE2A
SCHEMBL26619829 0.79 DPP4 (0.43) IDO1DPP4SLC6A2SLC6A4SLC6A3
SCHEMBL6815689 0.79 DPP4 (0.43) IDO1DPP4SLC6A2SLC6A4SLC6A3
SCHEMBL21725516 0.78 TRPV4 (0.42) ALDH1A1HPGD
SCHEMBL4547922 0.78 NOTUM (0.44) IDO1DPP4SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2021-04-20 US disclosed
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-01-07 US disclosed
US-20200216415-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2020-07-09 US disclosed
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R IDO1 782/4885DPP4 898/4885SLC6A2 341/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R IDO1 782/4885DPP4 898/4885SLC6A2 341/4885
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R IDO1 782/4885DPP4 898/4885SLC6A2 341/4885
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R IDO1 782/4885DPP4 898/4885SLC6A2 341/4885
US-20200216415-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R IDO1 782/4885DPP4 898/4885SLC6A2 341/4885
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R IDO1 782/4885DPP4 898/4885SLC6A2 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.